C
Prestige Consumer Healthcare Inc. PBH
$60.91 -$0.54-0.88% NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
EPS (TTM)

Company Overview

Prestige Consumer Healthcare Inc. is a U.S.-based consumer healthcare company focused on the marketing, manufacturing, and distribution of over-the-counter (OTC) healthcare and personal care products. The company operates within the consumer health and self-care industries, with a portfolio primarily composed of established, brand-name products that address everyday health needs. Its revenue is largely driven by sales of branded OTC medications and health-related consumer products sold through mass merchandisers, drugstores, grocery chains, and e-commerce platforms.

The company’s core strength lies in owning long-established brands with strong consumer recognition and defensible market positions, often acquired from larger pharmaceutical companies. Prestige Consumer Healthcare was originally founded in 1996 as Prestige Brands Holdings and went public in 2005. In 2017, the company rebranded as Prestige Consumer Healthcare Inc. to reflect its increased focus on healthcare-oriented products and international expansion rather than general consumer packaged goods.

Business Operations

Prestige Consumer Healthcare operates primarily through a single reportable segment: OTC Healthcare Products, which encompasses cough, cold, allergy, eye care, gastrointestinal, oral care, pain relief, women’s health, and dermatological products. Key revenue-generating brands include Clear Eyes, Dramamine, BC Powder, Chloraseptic, Summer’s Eve, DenTek, Compound W, and Hydralyte. The company generates revenue through product sales rather than research-driven pharmaceutical development, emphasizing brand management, marketing, and supply chain efficiency.

Operations are concentrated in North America, with additional international activities managed through wholly owned subsidiaries such as Prestige Brands International and Care Pharmaceuticals. Manufacturing is largely outsourced to third-party contract manufacturers, while the company retains control over branding, regulatory compliance, marketing strategy, and distribution relationships. This asset-light operating model allows Prestige Consumer Healthcare to maintain relatively high margins and predictable cash flows.

Strategic Position & Investments

Prestige Consumer Healthcare’s strategy centers on acquiring mature, under-marketed brands with stable demand and enhancing their performance through focused marketing, pricing optimization, and expanded distribution. Growth initiatives prioritize bolt-on acquisitions in the self-care and OTC healthcare space, particularly products with limited private-label competition and strong regulatory or brand barriers.

Notable acquisitions include C.B. Fleet (women’s health and gastrointestinal products), Hydralyte (oral rehydration solutions), and Care Pharmaceuticals, an Australia-based consumer healthcare company that expanded Prestige’s presence in the Asia-Pacific region. The company continues to invest in brand renovation, e-commerce capabilities, and selective international expansion, while avoiding early-stage drug development or high-risk R&D-intensive sectors.

Geographic Footprint

Prestige Consumer Healthcare is headquartered in the United States, with its principal executive offices located in New York. The majority of revenue is generated in the United States, which represents the company’s largest and most established market. Products are distributed nationally through major retail and online channels.

Internationally, the company maintains a growing presence in Canada, Australia, and parts of Europe, primarily through acquired subsidiaries and localized brand portfolios. While international markets contribute a smaller share of total revenue compared to the U.S., they are viewed as long-term growth opportunities supported by rising demand for self-care and OTC health solutions.

Leadership & Governance

Prestige Consumer Healthcare is led by an executive team with extensive experience in consumer packaged goods, healthcare marketing, and corporate finance. The leadership emphasizes disciplined capital allocation, brand stewardship, and consistent cash flow generation, with a strategic vision centered on long-term value creation through brand-focused growth rather than product innovation risk.

Key executives include:

  • Ronald M. LombardiPresident & Chief Executive Officer
  • Mark J. KaphammerExecutive Vice President & Chief Financial Officer
  • Kristin D. WilliamsExecutive Vice President & Chief Commercial Officer
  • Thomas J. AssanzaExecutive Vice President, Operations & Chief Supply Chain Officer
  • Michael O. ArchboldChairman of the Board

The board of directors and executive leadership oversee governance with a focus on regulatory compliance, risk management, and shareholder returns, consistent with the company’s position as a publicly traded consumer healthcare enterprise.

Data complied by narrative technology. May contain errors

Top Tech Stocks
See All »
B
NVDA NASDAQ $183.22
B
AAPL NASDAQ $252.82
B
MSFT NASDAQ $399.95
Top Consumer Staple Stocks
See All »
B
WMT NASDAQ $125.99
B
Top Financial Stocks
See All »
B
B
JPM NYSE $286.16
B
V NYSE $310.11
Top Energy Stocks
See All »
B
ENB.TO TSX $73.47
B
ENB NYSE $54.54
Top Health Care Stocks
See All »
B
LLY NYSE $989.12
B
JNJ NYSE $243.19
B
AMGN NASDAQ $366.25
Top Real Estate Stocks
See All »
B
PLD NYSE $133.00